Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Dose Escalation and Expansion Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 as Monotherapy and in Combination With Other Anticancer Agents in Adults With Advanced Solid Malignancies

NCT04244552 is registered in ClinicalTrials.gov with Atreca, Inc. as lead sponsor.

NCT NCT04244552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04244552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Dose Escalation and Expansion Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 as Monotherapy and in Combination With Other Anticancer Agents in Adults With Advanced Solid Malignancies
Lead sponsor
Atreca, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
February 11, 2020
Completion date
November 1, 2023
Enrollment
87 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

acral lentiginous melanoma, breast cancer, colorectal cancer, dmmr colorectal cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, melanoma, msi-h colorectal cancer, non-small cell lung cancer, ovarian cancer, platinum-resistant epithelial ovarian cancer, platinum-resistant fallopian tube carcinoma, platinum-resistant primary peritoneal carcinoma, triple negative breast cancer, urothelial carcinoma